AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as 'Ajinomoto') has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as 'RIBOMIC'), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology 'AJICAP®' (hereinafter referred to as 'AJICAP®'). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream.